A study to find out whether Odronextamab is safe and well tolerated and how effective it is compared to Rituximab in combination with different types of chemotherapy in participants with follicular lymphoma
Summary description of the study
The study investigates the drug Odronextamab, referred to as the investigational product. The study focuses on patients with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma, NHL). The study is divided into Part 1 and Part 2. The aim of Part 1 of the study is to determine how safe and well tolerated the investigational product is. The aim of Part 2 of the study is to investigate the effect of Odronextamab compared to Rituximab and chemotherapy (the current standard treatment for non-Hodgkin lymphoma). Several research questions are explored in the study, including: • What side effects can the investigational product cause? • How much of the investigational product is present in the blood at different times? • Does the body produce antibodies against the investigational product (which could make the drug less effective or lead to side effects)? • The effects of the investigational product on the quality of life and daily functioning of the patients.
(BASEC)
Intervention under investigation
Odronextamab is a monoclonal antibody described as bispecific because it can individually recognize and bind to 2 cell proteins (CD20 and CD3). Proteins are part of every cell in the body, working like small machines to ensure the function of the cell. CD20 is a protein found on the surface of both normal B cells and B cells that form certain cancers, such as follicular lymphoma. CD3 is a protein found on the surface of T cells. T cells and normal B cells are types of white blood cells in the body and are part of the immune system that fights infections. Odronextamab is intended to help T cells find and kill B cells, including cancer cells in follicular lymphoma.
(BASEC)
Disease under investigation
Participants must be at least 18 years old and have untreated follicular lymphoma.
(BASEC)
– Participants must be at least 18 years old – have follicular lymphoma – Participants have not received prior treatment for follicular lymphoma (BASEC)
Exclusion criteria
– Participants with follicular lymphoma that has occurred in the brain or has spread to the brain (known as leptomeningeal involvement) or with certain cancers such as central nervous system lymphoma, high-grade follicular lymphoma (also referred to as type 3b) or with diffuse large B-cell lymphoma – Participants with uncontrolled hepatitis B, uncontrolled hepatitis C, or uncontrolled HIV infections (human immunodeficiency virus). If your blood tests positive for cytomegalovirus (CMV), you must receive treatment for that and show a negative test result on two occasions at least one week apart before you can be included in the study. – Pre-existing conditions of the brain and spinal cord, as described in the study protocol (BASEC)
Trial sites
Basel, Bern, St. Gallen, Winterthur, Zurich, Other
(BASEC)
Baden
(BASEC)
Sponsor
ICON Clinical Research GmbH Switzerland
(BASEC)
Contact
Contact Person Switzerland
Clinical Trials Administrator
+1 844-734-6643
clinicaltrials@clutterregeneron.comRegeneron Pharmaceuticals, Inc.
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee northwest/central Switzerland EKNZ
(BASEC)
Date of authorisation
29.11.2023
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
Eine offene, randomisierte Phase-III-Studie zum Vergleich der Wirksamkeit und Sicherheit von Odronextamab (REGN1979), einem bispezifischen Anti-CD20 x Anti-CD3-Antikörper, gegenüber der Wahl des Prüfarztes bei zuvor unbehandelten Teilnehmern mit follikulärem Lymphom (OLYMPIA-1) (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available